Innate Pharma to attend Kempen Life Sciences event
Innate Pharma S.A., a clinical-stage biotechnology company developing cancer immunotherapies, reported that its executive team will participate in one-on-one investor meetings at the Kempen Life Sciences Conference in Amsterdam on April 15–16, 2026.
Rhea-AI Filing Summary
Innate Pharma S.A., a clinical-stage biotechnology company developing cancer immunotherapies, reported that its executive team will participate in one-on-one investor meetings at the Kempen Life Sciences Conference in Amsterdam on April 15–16, 2026.
The company highlights its portfolio of antibody-based therapies, including IPH4502, lacutamab and monalizumab, and notes ongoing collaborations with major partners such as AstraZeneca and Sanofi. The notice also reiterates that investors should refer to its French Universal Registration Document and Form 20-F for detailed risk factors.
Positive
- None.
Negative
- None.
Key Figures
Conference dates: April 15–16, 2026
Report date: April 3, 2026
Press release time: 7:00 A.M. CEST
+2 more
5 metrics
Conference dates
April 15–16, 2026
Kempen Life Sciences Conference in Amsterdam
Report date
April 3, 2026
Date of Innate Pharma announcement
Press release time
7:00 A.M. CEST
Time of Innate Pharma communication from Marseille
ISIN code
FR0010331421
Identifier for Innate Pharma shares
LEI
9695002Y8420ZB8HJE29
Legal Entity Identifier for Innate Pharma
Key Terms
clinical-stage biotechnology company, immunotherapies, antibody-drug conjugate, Universal Registration Document, +2 more
6 terms
clinical-stage biotechnology company financial
"Innate Pharma SA ... a clinical-stage biotechnology company developing immunotherapies for cancer patients"
immunotherapies medical
"a clinical-stage biotechnology company developing immunotherapies for cancer patients"
Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.
antibody-drug conjugate medical
"IPH4502, a differentiated Nectin-4 ADC developed in solid tumors"
An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.
Universal Registration Document regulatory
"refer to the Risk Factors ... section of the Universal Registration Document filed with the French Financial Markets Authority"
A universal registration document is a single, comprehensive filing that collects a publicly traded company's key disclosures — such as business description, financial statements, risk factors, governance and legal information — into one place for regulators and investors. Think of it as a detailed owner’s manual and scorecard combined: it saves time when the company issues new shares or bonds and helps investors compare, check risks, and make informed decisions without hunting through many separate reports.
Annual Report on Form 20-F regulatory
"including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025"
An annual report on Form 20-F is a standardized filing that foreign companies submit to the U.S. securities regulator to disclose their financial results, business operations, risks, and management’s discussion of performance. It matters to investors because it provides a complete, audited snapshot—like a company’s financial report card and shareholder letter combined—used to assess transparency, compare companies, and judge whether the stock’s price matches underlying business strengths and risks.
immuno-oncology medical
"to advance innovation in immuno-oncology"
Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Innate Pharma (IPHA) announce in this 6-K filing?
Innate Pharma announced its executive team will attend the Kempen Life Sciences Conference for one-on-one investor meetings. The company also reiterates its focus on developing antibody-based immunotherapies for cancer and refers readers to its regulatory filings for detailed risk factors.
When and where is Innate Pharma (IPHA) attending the Kempen Life Sciences Conference?
Innate Pharma executives will participate in the Kempen Life Sciences Conference on April 15–16, 2026 in Amsterdam, Netherlands. The company plans one-on-one investor meetings at the event, highlighting its oncology pipeline and collaborations with major pharmaceutical partners.
What type of company is Innate Pharma (IPHA)?
Innate Pharma is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. It focuses on antibody-engineering and innovative target identification to create differentiated next-generation antibody therapeutics, supported by collaborations with partners such as Sanofi, AstraZeneca and leading research institutions.
Which key drug candidates are highlighted by Innate Pharma (IPHA)?
Innate Pharma highlights several key oncology candidates: IPH4502, a Nectin-4 antibody-drug conjugate for solid tumors; lacutamab, an anti-KIR3DL2 antibody for T cell lymphomas; and monalizumab, an anti-NKG2A antibody developed with AstraZeneca for non-small cell lung cancer.
Where can investors find Innate Pharma (IPHA) risk factors and regulatory information?
Investors can review Innate Pharma’s risk factors in its Universal Registration Document filed with the French AMF and its Annual Report on Form 20-F filed with the SEC. These documents, along with subsequent filings, are accessible via the AMF website and the company’s website.
AI-generated analysis. How Rhea-AI works. Not financial advice.
